Silverarc Capital Management
Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Spdr S&p Oil & Gas Exp & Pr put, Kalvista Pharmaceuticals, DNTH, COGT, CELC, and represent 31.60% of Silverarc Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Spdr S&p Oil & Gas Exp & Pr put (+$105M), ZBIO (+$22M), Ascendis Pharma A S (+$17M), SRRK (+$17M), ALKS (+$16M), GLUE (+$16M), IMNM (+$16M), RYTM (+$15M), IRON (+$13M), HLXC (+$12M).
- Started 25 new stock positions in GENB, ZBIO, IMVT, Spdr S&p Oil & Gas Exp & Pr put, CMPS, ALKS, ANNX, SRRK, XENE, IRON.
- Reduced shares in these 10 stocks: ABVX (-$13M), CGON (-$13M), VRDN (-$11M), PFE (-$10M), AVTX (-$9.5M), DNTH (-$8.0M), GOSS (-$6.6M), LXEO (-$6.1M), AMLX (-$6.1M), INSM (-$5.8M).
- Sold out of its positions in AMLX, AVTX, CTMX, FDMT, GOSS, Kalvista Pharmaceuticals, KYMR, LXEO, MLYS, OLMA. PALI, PFE, RAPP, RLAY, Soleno Therapeutics, TARS, Ultragenyx Pharmaceutical In, VRDN, XFOR, QURE.
- Silverarc Capital Management was a net buyer of stock by $203M.
- Silverarc Capital Management has $980M in assets under management (AUM), dropping by 36.08%.
- Central Index Key (CIK): 0001816307
Tip: Access up to 7 years of quarterly data
Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 73 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Series Trust Put Put Option | 10.8 | $105M | NEW | 825k | 127.73 |
|
| Kalvista Pharmaceuticals | 5.9 | $58M | +18% | 2.9M | 20.13 |
|
| Dianthus Therapeutics (DNTH) | 5.6 | $55M | -12% | 655k | 83.92 |
|
| Cogent Biosciences (COGT) | 5.2 | $51M | +5% | 1.3M | 38.49 |
|
| Celcuity (CELC) | 4.2 | $41M | -4% | 358k | 114.14 |
|
| Immunome (IMNM) | 4.1 | $41M | +64% | 1.9M | 21.87 |
|
| Kodiak Sciences (KOD) | 3.9 | $38M | -3% | 992k | 38.12 |
|
| Nuvalent Inc-a (NUVL) | 3.7 | $36M | +13% | 355k | 102.45 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.4 | $34M | -28% | 303k | 111.35 |
|
| Monte Rosa Therapeutics (GLUE) | 3.4 | $33M | +94% | 2.0M | 16.45 |
|
| Erasca (ERAS) | 3.1 | $30M | +40% | 1.9M | 16.18 |
|
| Ascendis Pharma A/s Sponsored Adr | 2.9 | $29M | +153% | 125k | 228.73 |
|
| Urogen Pharma (URGN) | 2.8 | $27M | -13% | 1.5M | 17.98 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.7 | $27M | +125% | 306k | 86.97 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.4 | $23M | -13% | 72k | 322.19 |
|
| Zenas Biopharma (ZBIO) | 2.3 | $22M | NEW | 1.1M | 19.55 |
|
| Syndax Pharmaceuticals (SNDX) | 2.1 | $21M | +38% | 889k | 23.36 |
|
| Centessa Pharmaceuticals Sponsored Ads | 1.9 | $19M | 466k | 39.72 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 1.7 | $17M | NEW | 340k | 49.16 |
|
| Alkermes SHS (ALKS) | 1.7 | $16M | NEW | 460k | 35.36 |
|
| Oric Pharmaceuticals (ORIC) | 1.4 | $14M | 1.1M | 12.67 |
|
|
| Disc Medicine (IRON) | 1.3 | $13M | NEW | 196k | 63.94 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 1.3 | $12M | NEW | 1.2M | 10.16 |
|
| Xenon Pharmaceuticals (XENE) | 1.2 | $12M | NEW | 198k | 58.15 |
|
| Cg Oncology (CGON) | 1.1 | $11M | -53% | 166k | 67.68 |
|
| Immunovant (IMVT) | 1.1 | $10M | NEW | 414k | 24.84 |
|
| Spyre Therapeutics Com New (SYRE) | 1.0 | $9.4M | 187k | 50.44 |
|
|
| Biogen Idec (BIIB) | 1.0 | $9.3M | -32% | 51k | 183.33 |
|
| Guardant Health (GH) | 0.9 | $9.1M | +7% | 99k | 92.37 |
|
| Vaxcyte (PCVX) | 0.9 | $8.4M | -2% | 145k | 58.11 |
|
| Uniqure Nv Call Call Option | 0.8 | $8.2M | -30% | 500k | 16.35 |
|
| Savara (SVRA) | 0.8 | $7.8M | NEW | 1.4M | 5.46 |
|
| Benitec Biopharma Com New (BNTC) | 0.8 | $7.6M | 718k | 10.65 |
|
|
| Syndax Pharmaceuticals Call Call Option | 0.8 | $7.5M | NEW | 320k | 23.36 |
|
| Oruka Therapeutics (ORKA) | 0.8 | $7.4M | NEW | 151k | 49.05 |
|
| Compugen Ord (CGEN) | 0.7 | $7.1M | -4% | 3.3M | 2.13 |
|
| Celcuity Call Call Option | 0.6 | $6.2M | NEW | 55k | 114.14 |
|
| Trevi Therapeutics (TRVI) | 0.6 | $6.1M | -5% | 511k | 11.93 |
|
| Insmed Com Par $.01 (INSM) | 0.6 | $5.9M | -49% | 36k | 163.52 |
|
| Veracyte (VCYT) | 0.6 | $5.8M | -49% | 180k | 32.21 |
|
| Cerus Corporation (CERS) | 0.6 | $5.8M | +12% | 3.2M | 1.82 |
|
| Celldex Therapeutics Com New (CLDX) | 0.6 | $5.7M | -6% | 178k | 31.72 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $5.0M | -4% | 1.9M | 2.63 |
|
| Cytokinetics Com New (CYTK) | 0.5 | $4.7M | NEW | 71k | 65.91 |
|
| Eliem Therapeutics (CLYM) | 0.5 | $4.7M | NEW | 685k | 6.85 |
|
| Compass Therapeutics (CMPX) | 0.5 | $4.5M | -18% | 859k | 5.29 |
|
| Surrozen Com New (SRZN) | 0.4 | $4.2M | -8% | 144k | 29.13 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.4 | $3.9M | 302k | 13.06 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $3.3M | NEW | 561k | 5.95 |
|
| Fulcrum Therapeutics (FULC) | 0.3 | $3.2M | +6% | 420k | 7.67 |
|
| Fulcrum Therapeutics Call Call Option | 0.3 | $3.0M | 392k | 7.67 |
|
|
| Abeona Therapeutics Com New (ABEO) | 0.3 | $2.9M | +3% | 649k | 4.48 |
|
| Camp4 Therapeutics Corp (CAMP) | 0.3 | $2.9M | NEW | 654k | 4.41 |
|
| Annexon (ANNX) | 0.3 | $2.8M | NEW | 497k | 5.54 |
|
| Elutia Cl A Com (ELUT) | 0.3 | $2.6M | -9% | 2.5M | 1.05 |
|
| Crescent Biopharma (CBIO) | 0.2 | $2.4M | NEW | 131k | 18.37 |
|
| Monopar Therapeutics Com New (MNPR) | 0.2 | $2.4M | NEW | 44k | 54.79 |
|
| Ovid Therapeutics (OVID) | 0.2 | $2.2M | NEW | 1.0M | 2.22 |
|
| Nextcure Com New (NXTC) | 0.2 | $1.9M | 176k | 10.68 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $1.7M | NEW | 300k | 5.53 |
|
| Neumora Therapeutics (NMRA) | 0.2 | $1.6M | NEW | 818k | 1.95 |
|
| Sionna Therapeutics (SION) | 0.2 | $1.6M | -4% | 39k | 40.09 |
|
| Tela Bio (TELA) | 0.1 | $1.4M | -14% | 2.3M | 0.62 |
|
| Edgewise Therapeutics (EWTX) | 0.1 | $1.3M | 43k | 31.50 |
|
|
| Replimune Group (REPL) | 0.1 | $1.3M | NEW | 172k | 7.65 |
|
| Generate Biomedicines Com Shs (GENB) | 0.1 | $1.3M | NEW | 100k | 12.50 |
|
| Compass Therapeutics Call Call Option | 0.1 | $912k | NEW | 172k | 5.29 |
|
| Radiopharm Theranostics Sponsored Ads (RADX) | 0.1 | $806k | 187k | 4.30 |
|
|
| Fractyl Health (GUTS) | 0.1 | $779k | -82% | 1.7M | 0.46 |
|
| Ibio Com New (IBIO) | 0.0 | $429k | +113% | 226k | 1.90 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $290k | -51% | 252k | 1.15 |
|
| Aardvark Therapeutics (AARD) | 0.0 | $127k | -88% | 34k | 3.77 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $2.2k | 105k | 0.02 |
|
Past Filings by Silverarc Capital Management
SEC 13F filings are viewable for Silverarc Capital Management going back to 2020
- Silverarc Capital Management 2026 Q1 filed May 14, 2026
- Silverarc Capital Management 2025 Q4 filed Feb. 12, 2026
- Silverarc Capital Management 2025 Q3 filed Nov. 12, 2025
- Silverarc Capital Management 2025 Q2 filed Aug. 14, 2025
- Silverarc Capital Management 2025 Q1 filed May 14, 2025
- Silverarc Capital Management 2024 Q4 filed Feb. 14, 2025
- Silverarc Capital Management 2024 Q3 filed Nov. 14, 2024
- Silverarc Capital Management 2024 Q2 filed Aug. 14, 2024
- Silverarc Capital Management 2024 Q1 filed May 15, 2024
- Silverarc Capital Management 2023 Q4 filed Feb. 14, 2024
- Silverarc Capital Management 2023 Q3 filed Nov. 13, 2023
- Silverarc Capital Management 2023 Q2 filed Aug. 14, 2023
- Silverarc Capital Management 2023 Q1 filed May 15, 2023
- Silverarc Capital Management 2022 Q4 filed Feb. 14, 2023
- Silverarc Capital Management 2022 Q3 filed Oct. 28, 2022
- Silverarc Capital Management 2022 Q2 filed July 25, 2022